Our coverage of PreveCeutical Medical (PRVCF) is updated with comments on recent progress with the Company’s portfolio of research and development projects focused on preventative therapeutics. The Company has several major achievements in recent months, moving the R&D pipeline closer to goals.
In March 2018, the Company’s research and development partner UniQuest Pty. Ltd. began testing dried cannabis flower shipped from the Company’s U.S. supplier under strict restricted substance laws in effect in the U.S. and Australia. Once the cannabis material is fully analyzed its cannabidiol features will be used as the first therapeutic compound developed for the Company’s Sol-Gel nose-to-brain drug delivery system. The Company has also begun a search for a compatible delivery device that patients will use to apply Sol-Gel. At least one manufacturer has signed a letter of non-disclosure to enable detailed discussions about its own device development capabilities and compatibility with Sol-Gel.
The Company also moved forward with its Smart siRNA program to develop an effective treatment for obesity and diabetes. Staffing and organizational efforts begin in the first quarter 2018. Laboratory equipment appropriate for the first steps in identifying target diseased genes is already in place.
In January 2018, PreveCeutical extended the pact with UniQuest to access it’s disulfide linker technology. The platform will be used to identify blue scorpion venom peptides for non-addictive analgesics.
Click on the image below to view the full ten-page report.
Please read the important disclosures and disclaimers on the final page of all Crystal Equity Research publications.